Design Therapeutics Inc. (DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, has a couple of clinical trial catalysts to watch in the second half of this year.
The company is developing a portfolio of GeneTAC drug candidates aimed at treating genetic diseases caused by repeated DNA sequences. These GeneTAC molecules are a new type of small-molecule medicine designed to target the root cause of disease. They work by either increasing or decreasing the activity of a specific faulty gene, helping to correct the problem rather than just treating symptoms.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com